Soft Tissue Tumors in Adults: ESSR–Approved Guidelines for Diagnostic Imaging

ARTICLE in SEMINARS IN MUSCULOSKELETAL RADIOLOGY · DECEMBER 2015
Impact Factor: 1.09 · DOI: 10.1055/s-0035-1569251

16 AUTHORS, INCLUDING:

Filip M Vanhoenacker
Algemeen ziekenhuis Sint-Maarten
377 PUBLICATIONS  3,198 CITATIONS

Joan C Vilanova
Universitat de Girona
190 PUBLICATIONS  1,095 CITATIONS

All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.

Available from: Joan C Vilanova
Retrieved on: 26 December 2015
Abstract

Soft tissue sarcomas are rare, but early, accurate diagnosis with subsequent appropriate treatment is crucial for the clinical outcome. The ESSR guidelines are intended to help radiologists in their decision-making and support discussion among clinicians who deal with patients with suspected or proven soft tissue tumors. Potentially malignant lesions recognized by ultrasound should be referred for magnetic resonance imaging (MRI), which also serves as a preoperative local staging modality, with specific technical requirements and mandatory radiological report elements. Radiography may add information about matrix calcification and osseous involvement. Indeterminate lesions, or lesions in which therapy is dependent on histology results, should be biopsied. For biopsy, we strongly recommend referral to a specialist sarcoma center, where an interdisciplinary tumor group, with a specialized pathologist, radiologist, and the surgeon are involved. In sarcoma, a CT scan of the chest is mandatory. Additional
Rationale and Objective of the ESSR Guidelines

Soft tissue tumors are rare and represent a diverse group of heterogeneous entities. Sarcomas account for only ~1% of soft tissue tumors in adults. Early accurate diagnosis and appropriate treatment are crucial for optimum outcome. Therefore, regularly updated guidelines for diagnostic strategy containing both minimal requirements and recommendations for optimization are required.

The European Society of Musculoskeletal Radiology (ESSR) guidelines are not meant to be prescriptive but are intended to help radiologists in their decision management and to support discussion among clinicians who deal with suspected or proven soft tissue tumors. We are aware that variations exist between countries and that the procedure varies in a minority of patients with special entities. We wish to stress the role of specialist sarcoma treatment centers, especially in cases of uncertainty and to avoid procedures when sarcomas become evident only during surgery, resulting in intralesional resection. We strongly recommend referral to a specialist sarcoma center for biopsy in indeterminate or likely malignant tumors.

History and Clinical Features

The following information should be available for the radiologist:

History: (a) Has there been a recent trauma (caveat: many patients report trauma that may be unrelated and misleading)? (b) Is the patient anticoagulated? (c) When did the patient first notice the lesion? Is it growing, and how fast? (d) Does it change in size (e.g., dependent on position, exercise, or muscle contraction/relaxation)? (e) Is there any oncologic history (malignancy, chemotherapy, or radiotherapy)? (f) Is there history of previous surgery?

A standardized checklist, primarily filled out by the patient, and discussed with the radiologist, is considered advisable.

Clinical symptoms and palpation: (a) Is the lesion painful? (b) Is it palpable, and if so, is it hard or soft? (c) Is it movable against the skin and underlying tissue? (d) Are there skin alterations or pathologic vessels? (e) Single or multiple lesions?

Primary Imaging

Patients with palpable lumps and suspected soft tissue tumor are numerous, resulting in a high initial workload, but imaging should be performed in most. Unless a lesion is clinically suspicious for malignancy (> 5 cm, deep, firm, and fixed on palpation), a reliable primary-triage image modality, in combination with clinical features, can be used to decide which patients need further work-up and who should be referred to a dedicated tumor center.

Ultrasound

In patients with a suspected soft tissue tumor, ultrasound (US) is considered the appropriate initial triage imaging modality as long as the tumor is accessible by US. The presence of a soft tissue tumor can be confirmed, but characterization is limited, and intra-articular and osseous involvement cannot be diagnosed reliably. US is readily available, “real time,” radiation free, and cost effective but depends on the skill of the sonographer and may be challenging in obese patients. Reproducibility and reliability depend on appropriate documentation. Although US is excellent for the detection of even very small lesions, it may miss lesions in deep locations. Small areas of scar tissue can be misinterpreted as recurrence in patients who have had previous surgery.

Technical Ultrasonography Standards

Mandatory requirements: The US hardware should be quality assured, images stored in a picture archival communication system, and a written report available for each examination.

State-of-the-art scanners should be used, with high-resolution transducers (frequency dependent on the depth of the lesion) and color/power Doppler available. Extended field of view and compound imaging are desirable. If no mass is detected initially, frequency harmonic imaging for echo-poor solid masses may be useful.

Who Should Perform the Initial Ultrasound?

Ideally, a board-certified radiologist (or, in the clinical setting, a radiologist with proven experience in sonographic soft tissue lesion assessment) should perform the US. We consider the radiologist (who also has access to other imaging modalities) the most suitable medical specialist for this issue. Purely cutaneous lesions can be assessed by a dermatologist, if specifically trained.

What Should Be Described on Ultrasound?

- Relation to the fascia (superficial, deep), exact anatomical location including compartmental involvement, the
relationship to/infiltration of vessels/nerve, and, if possible, joints and/or bone and crucial adjacent structures.
- Size (in three dimensions).
- Morphology: cystic, solid (intralessional echo texture, vascularization, presence or absence of necrosis, bleeding, posterior acoustic enhancement/shadowing, suspected calcifications), shape, borders/margins.

Criteria for Diagnosis of a Benign Lesion
- Simple cyst, bursa, synovial/ganglion cyst: purely cystic well-defined lesion without any solid component, anechoic, with posterior acoustic enhancement and no internal vascularity.\(^8\)
- Superficial lipoma: homogeneous well defined, encapsulated, and compressible with no clinical concern and documented stability on US (at least 6 months follow-up).\(^9,10\)
- Vascular malformation with no clinical concern and stability on US (at least 6 months follow-up).\(^11\)
- Foreign body “granuloma” with a compatible history.\(^12\)
- Superficial fibromas (e.g., palmar and plantar fibromatosis, infantile digit fibromatosis).\(^13,14\)
- Muscle hernia.\(^15\)
- Morton neurona.\(^16\)
- Peripheral nerve sheath tumors only in case of proven neurofibromatosis for the detection and monitoring of typical neurofibromas. If painful, additional investigations should be conducted.\(^11,17\)

Criteria for Follow-up by Ultrasound
- Likely posttraumatic hematoma or follow-up of muscle tears (follow-up interval: depending on the size, 3–6 weeks).
- Follow-up or preoperative evaluation of soft tissue mass previously characterized by MRI, no surgery intended, or before surgery.

Criteria for Proceeding to a Subsequent MRI
- Any tumor with a reasonable chance of being malignant.\(^18\)
- Location: below the superficial muscle fascia, or superficial, but obtuse contact with or crossing of the superficial fascia.\(^19,20\)
- Size > 5 cm.\(^21\)
- Any clinical or sonographic doubt (i.e., cannot be positively diagnosed as benign)
- Tumor at the site of a previous excision, regardless of previous histology
- Any tumor that is not completely accessible by US

Primary MRI should be considered instead of US in the following indications:
- Clinical suspicion of malignancy: suspicious clinical examination (fixed lump, large mass), deep mass, persistent swelling after trauma, rapidly enlarging lesion (except small superficial lesions), osseous involvement, joint involvement.
- In every case of abdominal/pelvic/retroperitoneal/paravertebral mass lesion detected incidentally with other imaging modalities (alternatively, a CT scan can be performed in these cases; see later).

Primary CT should be considered instead of US when the lesion is intrathoracic or intra-abdominal (including pelvic and retroperitoneal lesions). CT after US should be considered where there are contraindications to MRI (such as pacemakers) or when MRI is not available (for other CT indications, see later).

Projection radiography serves as a complementary imaging modality to show and characterize soft tissue calcification or ossification and bone involvement, particularly in deep palpable lesions, para-articular lesions, and large masses. For regions with a complex anatomy (e.g., axial skeleton, head/neck, thoracic, and pelvic areas), CT is preferred over radiography.

Further Imaging
MRI
MRI is the imaging method with the best soft tissue contrast. It serves to further characterize the tumor and provide precise and reproducible local staging for therapy planning and selecting appropriate biopsy regions.\(^24\)

MRI should preferably be performed in a sarcoma treatment center or by a radiologist with sufficient expertise in musculoskeletal radiology (MSK) (e.g., an ESSR diploma holder or a national MSK certification holder), with the potential to provide the electronic data set to a tumor center, if necessary.

Technical MRI Requirements
The field strength of the scanner should be at least 1 T, but preferentially 1.5-T or 3-T units should be used. A cutaneous marker should be applied. The field of view should be as large as necessary to image the entire lesion, peritumoral edema, and a layer of adjacent normal tissue, and to image non-palpable masses reliably (usually this aspect is especially important in coronal or sagittal sequences). Axial sequences with high spatial resolution are important to define tumor margins, tissue and compartment involvement, and neurovascular, bone, and joint involvement. The matrix should be optimized to achieve high in-plane spatial resolution, high signal-to-noise ratio, and a reasonable examination time (e.g., 256; if possible 384, or [in T1-weighted, T2-weighted] even 512). The slice thickness should not exceed 4 mm. In smaller tumors, 3-mm slices may be appropriate.

The tumor should be measured in three dimensions (sequences should be performed in at least two planes). At least one sequence should include an external bony landmark for measuring and operation planning.\(^26\)

Recommended basic protocols include T1-weighted and a fluid-sensitive, fat-saturated (FS) sequence, both parallel to the long axis of the tumor. An axial T2-weighted sequence may provide further information about the tumor matrix.\(^26–28\) Some authors use only axial proton-density FS or T2 FS; one of these should be performed. We recommend using intravenous gadolinium-based contrast agents, if
possible and feasible, at a routine dosage (usually 0.1 mmol/kg body weight). In patients with renal insufficiency, the European Society of Urogenital Radiology guidelines should be taken into account.\(^{29}\) Postcontrast sequences should be performed in two planes (routinely, the T1-weighted precontrast sequence along the long axis is repeated, and a FS T1-weighted axial sequence is performed). Subtraction images (T1-weighted pre-subtracted from T1-weighted postcontrast) help identify truly enhancing tumor areas sensitively.

Additional sequences may include dynamic contrast enhancement and diffusion-weighted sequences that can be helpful in characterizing the tumor (especially vascularization and matrix) but are not currently mandatory.\(^{30,32}\) Pretreatment dynamic MR studies are useful as a baseline for follow-up MR scans to monitor response to chemotherapy.

What Should Be Described on the MRI Report?

- Lesion location and extension\(^{26}\)
- Relation to the fascia (superficial, deep), exact anatomical location, with relationship to/infiltration of vessels/nerves, joints, and/or bone, muscles/compartment,\(^{33}\) and distance to external landmark.
- Size (in three dimensions)

Lesion morphology:

- Cystic, solid (matrix signal intensity, homogeneity, vascularity, enhancement, with and without necrosis, bleeding).
- Borders, lobularity, pseudocapsule, perifocal edema, and surrounding alterations
- Multiplicity and satellite lesions, abnormal proximal lymph nodes.\(^{26}\)

Criteria for a Determinate Lesion on MRI

The following lesions may be reliably characterized on MRI: lipoma, ganglion cyst, Baker cyst, bursitis, vascular malformation, hematoma, myositis ossificans, peripheral nerve sheath tumor (neurofibromas/schwannomas), muscle tear, pigmented villonodular synovitis (PVNS), and aneurysm.\(^{34}\)

If there is any doubt about tissue characterization, the patient should be referred to a sarcoma treatment center for a second opinion.\(^{35}\)

Referral to a Sarcoma Treatment Center

Patients with soft tissue tumors should be referred regularly to a sarcoma treatment center for a primary or a secondary opinion. Soft tissue sarcomas should be managed by a multidisciplinary sarcoma team that includes an (orthopedic) tumor surgeon, musculoskeletal radiologist, oncologist, and musculoskeletal pathologist. Further members of the team would include radiotherapists, specialized physiotherapists, and so on.

Criteria for referral to a sarcoma treatment center:

- Any patient with a \(\geq 5\)-cm superficial tumor or with a deep-seated tumor regardless of size.\(^{36}\)
- Indeterminate US or indeterminate MRI findings, or clinical suspicion of malignancy.
- Patients should be referred before biopsy or surgery.

Time intervals: The patient should ideally be reviewed by the sarcoma team and biopsied, if necessary, within 2 weeks.

Criteria for Subsequent Biopsy

A biopsy (usually image guided; for excisional or non–image-guided biopsy, see later) is indicated when the lesion is either indeterminate or if there is a likelihood of the lesion being malignant. In most cases, biopsy is necessary.

Biopsy

It is essential that the biopsy be performed in the sarcoma treatment center where the patient will receive further/definitive treatment\(^{36}\) (with the future oncologic surgeon and a specialized pathologist involved). The decision to biopsy or not should be arrived at by a multidisciplinary approach including the oncologic surgeon.

Biopsy Technique

In most patients, the method of choice is closed image-guided biopsy. In tumors \(\leq 3\) cm, particularly in superficial lesions, excisional biopsy may be appropriate. Rarely, for large and superficial lesions known to be homogeneous on recent imaging, non–image-guided biopsy may be appropriate.

Image-guided biopsy is minimally invasive, does not require general anesthesia or hospitalization, and has reasonable accuracy.\(^{37}\) Therefore, when the tumor is accessible, it is preferred over open biopsy (which is also appropriate).

Image-guided biopsy can be performed by US, MRI, or CT. US is recommended, especially in superficial, smaller, and homogeneous lesions. MRI or CT are especially preferred in thoracic, abdominal, or pelvic lesions. In practice, the choice depends on local expertise and the availability of imaging modalities.

It is essential to target viable tumor areas, identified by color Doppler US,\(^{38,39}\) contrast-enhanced MRI,\(^{40}\) or positron emission tomography (PET)/CT.\(^{41}\) Contrast-enhanced US and dynamic contrast-enhanced MRI\(^{42}\) can help target representative areas.

The biopsy approach should be planned in collaboration with the sarcoma surgeon because the biopsy tract has to be removed en bloc at the time of surgery. Contamination of nonaffected compartments should be avoided. Core biopsy is appropriate. Fine-needle aspiration biopsy is inappropriate.\(^{44}\) We recommend a biopsy needle size of at least 14G (most appropriate), and taking more than three or four samples.\(^{28}\)

Image-guided biopsy should be performed by a trained radiologist or the surgeon of the multidisciplinary tumor group in the sarcoma center after interdisciplinary discussion.

Proven Sarcoma: Further Imaging

In patients with histologically proven sarcoma, whole-body staging must be performed. When these results become available, further treatment should be planned by a multidisciplinary tumor board.
Whole-Body Staging

Staging should be performed according to the updated American Joint Committee on Cancer criteria\(^{45}\) that includes histologic grading according to the French Federation of Cancer Centers (considering cell differentiation, mitotic count, and tumor necrosis).

Metastatic spread of soft tissue sarcomas mainly is hematogenous, and pulmonary metastases are most common, accounting for \(\leq 75\) to \(80\%\) of metastases. CT of the chest (native three-dimensional volume helical CT with 1-mm reconstructions) is recommended. Other sites are less commonly involved. Osseous metastases occur in \(\approx 10\%\) of soft tissue sarcoma patients.\(^{46}\) Higher incidences have been described for alveolar soft part sarcoma,\(^{47,48}\) angiosarcoma,\(^{47}\) leiomyosarcoma,\(^{49}\) undifferentiated pleomorphic sarcoma,\(^{46}\) and dedifferentiated liposarcoma.\(^{47}\) Eighty percent of those osseous metastases are lytic,\(^{46}\) and fluorodeoxyglucose (FDG)-PET may be useful in these tumors.

Lymph node involvement is rare (\(\approx 3\%\) of sarcomas) and is more frequent in high-grade rhabdomyosarcoma, clear cell sarcomas, epithelioid sarcoma, angiosarcoma, and synovial sarcoma.\(^{50,51}\) Regional MRI/CT should be considered in those tumors.

In myxoid liposarcoma,\(^{52}\) epithelioid sarcoma,\(^{53}\) angiosarcoma,\(^{54}\) and leiomyosarcoma,\(^{55}\) abdominal CT should be considered. In alveolar soft part sarcoma with lung metastases,\(^{56,57}\) in clear cell sarcoma, and angiosarcoma,\(^{54}\) brain imaging should be considered.\(^{58}\) In myxoid liposarcoma,\(^{52}\) MRI of the spine should be considered.

The role of PET/CT and PET/MR for initial staging, therapy control, and follow-up is still regarded as controversial. It may lead to upstaging in only a minority of patients and is currently not recommended for routine use.\(^{59}\)

Follow-Up

To date, there are no evidence-based recommendations for routine follow-up in surgically treated sarcomas. In several European countries, follow-up is performed regularly for 10 years after the initial diagnosis.

Generally, a baseline examination 3 to 6 months postoperatively, followed by 3- to 6-month intervals up to the fifth year, and 12 months thereafter, are recommended in the American College of Radiology (ACR) appropriateness criteria.\(^{60}\) The recurrence rate is known to be influenced by the tumor grade.\(^{51}\) As proposed by the European Society of Medical Oncology (ESMO) and national societies, we recommend follow-up intervals that depend on tumor grade: for intermediate or high-grade sarcomas, intervals of 3 to 4 months in the first 2 to 3 years, and, in low-grade sarcomas, 4 to 6 months in the first 3 years; subsequently for both, 6-month intervals up to the fifth year.\(^{62-64}\) We also recommend 12-month intervals from the fifth to tenth years. In case of symptoms/suspected recurrence, follow-up can be performed earlier.

Apart from clinical and laboratory examinations, follow-up includes imaging for local recurrence and metastatic disease. There is debate about whether imaging should be

### Table 1 Whole-body staging in sarcoma

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest CT scan (unenhanced) for lung metastases</td>
<td>All soft tissue tumors</td>
</tr>
<tr>
<td>PET scan for osseous metastases</td>
<td>Alveolar soft part sarcoma(^{47,48})</td>
</tr>
<tr>
<td></td>
<td>Angiosarcoma(^{47})</td>
</tr>
<tr>
<td></td>
<td>Leiomyosarcoma(^{49})</td>
</tr>
<tr>
<td></td>
<td>Undifferentiated pleomorphic sarcoma(^{46})</td>
</tr>
<tr>
<td></td>
<td>Dedifferentiated liposarcoma(^{47})</td>
</tr>
<tr>
<td>Regional MRI/CT for lymph nodes</td>
<td>Rhabdomyosarcoma, clear cell sarcomas, epithelioid sarcoma, angiosarcoma, synovial sarcoma(^{50,51})</td>
</tr>
<tr>
<td>Abdominal CT</td>
<td>Myxoid liposarcoma(^{52})</td>
</tr>
<tr>
<td></td>
<td>Epithelioid sarcoma(^{53})</td>
</tr>
<tr>
<td></td>
<td>Angiosarcoma(^{54})</td>
</tr>
<tr>
<td></td>
<td>Leiomyosarcoma(^{55})</td>
</tr>
<tr>
<td>Brain imaging(^{58})</td>
<td>Alveolar soft part sarcoma(^{56})</td>
</tr>
<tr>
<td></td>
<td>Clear cell sarcoma, angiosarcoma(^{54})</td>
</tr>
<tr>
<td>MRI of the spine</td>
<td>Myxoid liposarcoma(^{52})</td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography.

### Table 2 Example for follow-up intervals

<table>
<thead>
<tr>
<th>Year after first treatment</th>
<th>Follow-up interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–3</td>
<td>Grading-dependent, every 3–4 mo</td>
</tr>
<tr>
<td>3–5</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>&gt; 5, up to 10</td>
<td>Annually</td>
</tr>
</tbody>
</table>

Consider tissue-specific additional modalities as detailed in Table 1

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.

Adapted from Mazeron and Suit.\(^{50}\)
Table 3  Key points

<table>
<thead>
<tr>
<th>Key Points 1: General Patient Information:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- The radiologist should be informed about the patient’s past medical history and clinical history/examination.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 2: Imaging Algorithm for Local Diagnosis:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Imaging should be performed in all patients with suspected soft tissue tumors.</td>
</tr>
<tr>
<td>- Ultrasound is considered the most appropriate initial triage modality for accessible tumors to clearly determine benign lesions.</td>
</tr>
<tr>
<td>- Any tumor with a reasonable chance of being malignant or at a previous excision site requires an MRI (or, in specific cases, CT).</td>
</tr>
<tr>
<td>- MRI, as the imaging modality with best soft tissue contrast, serves for further characterization of the tumor, local staging and therapy planning, and biopsy targeting.</td>
</tr>
<tr>
<td>- Projection radiography (or, in complex regions, CT) should be performed as an additive primary modality in deep palpable lesions, para-articular lesions, and large masses to characterize soft tissue calcification or ossification and bone involvement.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 3: Ultrasound Requirements:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Mandatory technical standards for ultrasound include quality-assured state-of-the-art scanners and transducers, archival image storage, and written examination reports.</td>
</tr>
<tr>
<td>- Radiologists with proven experience in soft tissue lesion assessment are considered most appropriate for initial ultrasound. Purely cutaneous lesions can be assessed by specifically trained dermatologists.</td>
</tr>
<tr>
<td>- Exact anatomical location, size, and morphology should be described.</td>
</tr>
<tr>
<td>- Only clearly benign, completely accessible lesions do not require further diagnostic work-up with imaging.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 4: MRI Requirements:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Mandatory technical standards for MRI include state-of-the-art scanners (field strengths of preferentially 1.5 T or 3 T, and at least 1 T) and coils.</td>
</tr>
<tr>
<td>- Cutaneous markers should be used, and at least one anatomical landmark should be visible.</td>
</tr>
<tr>
<td>- The field of view and the matrix should be optimized for the tumor size, and the tumor extent should be measurable in three dimensions.</td>
</tr>
<tr>
<td>- Fluid-sensitive fat-saturated and T1-weighted sequences obtained in at least two planes are minimal sequence requirements.</td>
</tr>
<tr>
<td>- Intravenous contrast agent is recommended in most cases; dynamic enhancement assessment and a static postcontrast sequence with subtraction are considered beneficial.</td>
</tr>
<tr>
<td>- Exact anatomical location, size, and morphology of the lesion should be described.</td>
</tr>
<tr>
<td>- Multiplicity, satellite lesions, and abnormal proximal lymph nodes should be described.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 5: Referral to Tumor Competence Center:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Defined by extensive expertise in the diagnosis and management of soft tissue tumors with a multidisciplinary sarcoma team that includes an orthopedic tumor surgeon, a musculoskeletal radiologist, and a musculoskeletal pathologist.</td>
</tr>
<tr>
<td>- Any patient with a ( \geq 5 ) cm superficial tumor, or with a deep-seated tumour, regardless of size.</td>
</tr>
<tr>
<td>- indeterminate ultrasound or MRI, or clinical suspicion of malignancy</td>
</tr>
<tr>
<td>- Before image-guided or excisional biopsy, or surgery.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 6: Whole-body Staging in Sarcoma:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Staging should be performed according to the updated AJCC criteria.</td>
</tr>
<tr>
<td>- Includes chest CT without contrast.</td>
</tr>
<tr>
<td>- Depending on the histologic entity, additional modalities are recommended (Table 1).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Points 7: Follow-up:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- No evidence-based recommendations exist, to date.</td>
</tr>
<tr>
<td>- Examples of imaging intervals with regular follow-up over 10 y, as performed in several ESSR countries, are supplied in Table 2.</td>
</tr>
</tbody>
</table>

Abbreviations: AJCC, American Joint Committee on Cancer; CT, computed tomography; ESSR, European Society of Musculoskeletal Radiology.
performed regularly\textsuperscript{18,60} or only in symptomatic cases.\textsuperscript{62} However, local recurrences are, especially in retroperitoneal lesions, desmoid type fibromatosis, and lesions with marked surrounding scar tissue, initially not palpable. We therefore recommend regular imaging. \textsuperscript{\textgreater \textless Table 2.}

In limb sarcomas, US seems promising for exclusion of local recurrence.\textsuperscript{65} To date, local MRI (including contrast-enhanced sequences) is considered the method of choice for local surveillance.\textsuperscript{24,66}

The follow-up MRI should be compared with the preoperative MRI (for morphology, site, and extent of the lesion). The MR protocol should include at least a fluid-sensitive, fat-saturated sequence (long and short axis), a T1-weighted sequence without contrast agent, and, in case of a focal mass, a T1-weighted sequence with contrast agent (with subtraction).\textsuperscript{67} A T2-weighted sequence may add to lesion morphology assessment and thus should be included in the protocol. If available and feasible, a delayed contrast enhancement and diffusion-weighted imaging sequence may be performed.\textsuperscript{67,68}

In case of metallic hardware, lower field strengths are preferred, and dedicated sequences that are optimized for minimizing susceptibility artifacts should be used. In case of large metallic hardware, US, dual-energy CT or CT using modern iterative reconstruction algorithms of raw data sets, or PET/CT can be considered as alternative or additive to MRI.

Chest CT (without contrast, helical three-dimensional volume acquisition with 1-mm reconstructions) is recommended for lung metastasis surveillance in accordance with ACR criteria\textsuperscript{60} because it is more sensitive than projection radiography.

Acknowledgments

We thank J. Panotopoulos and T. Brodowicz for their advice on clinical issues, and P. Szomolanyi for his help in preparing the manuscript.

Notes

Approved by the ESSR MSK Tumour Subcommittee.

References


Seminars in Musculoskeletal Radiology Vol. 19 No. 5/2015

Mazeron JJ, Suit HD. Lymph node sites as metastases from sarcomas of soft tissue. Cancer 1987;60(8):1800–1808


Roberge D, Vakilian S, Albedy AZ, Turcotte RE, Freeman CR, Hickson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma 2012;2012:960194


